Exploring New Strategies to Improve Outcomes in Small Cell Lung Cancer - Jazz Pharmaceuticals
Jazz Pharmaceuticals is highlighting the critical need for continued progress in treating extensive-stage small cell lung cancer (SCLC) during Lung Cancer Awareness Month. SCLC is an aggressive cancer where most patients relapse shortly after initial therapy. The company is exploring maintenance therapy research to help sustain disease control after first-line treatment.
Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
NeOnc, Nuvation, Jazz, and Cerenome are presenting new brain cancer data at the Society for Neuro-Oncology meeting. NeOnc (NTHI) highlighted NEO100's six-month progression-free survival of 48.9% and a median overall survival of 26.09 months, with an FDA Type B meeting scheduled for January 2027 to discuss accelerated approval. Jazz Pharmaceuticals (JAZZ) is advancing dordaviprone in a Phase 3 trial, while Cerenome (CNSY) will discuss SNO findings, its CNSide diagnostic business, and Q3 results on November 16.
No-Moat Jazz's Outlook Improved Thanks to Strong Data For Ziihera
Jazz Pharmaceuticals' outlook has improved due to strong data for its drug Ziihera, which supports growth beyond its core sleep franchise. The company's leading drug, Xyrem, faces generic pressure, but Ziihera's positive survival data in HER2-positive gastroesophageal cancer offers new opportunities.
Piper Sandler raises Jazz Pharmaceuticals price target on Ziihera outlook
Piper Sandler has increased its price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) to $330 from $310, maintaining an Overweight rating, driven by the strong outlook for Ziihera and the company's valuation. The firm anticipates double-digit growth from Ziihera in gastroesophageal adenocarcinoma and expects oxybate products to retain a significant role in hypersomnolence treatment. This positive outlook follows Jazz Pharmaceuticals' record third-quarter revenue, although the company reported a headline loss due to a significant R&D charge.
Jazz Pharmaceuticals (JAZZ) Faces A Fresh Valuation Test Following Mixed Earnings And Buyback
Jazz Pharmaceuticals recently reported mixed Q3 2026 earnings with a revenue increase but a net loss, alongside a new US$500 million share repurchase plan. Despite a 75% one-year total return, its US$248 share price is considered 16% undervalued by analysts, who estimate a fair value of $294.27, partly due to expected expansion of Ziihera. However, the company's high P/E ratio of 77.4x compared to the industry average of 14.6x suggests potential valuation risk if earnings don't meet expectations.
Price-Driven Insight from (JAZZ) for Rule-Based Strategy
This article provides a price-driven insight into Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), highlighting strong sentiment across all horizons and an overweight bias. It outlines three distinct AI-generated trading strategies—Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT)—with specific entry, target, and stop levels. The analysis emphasizes a mid-channel oscillation pattern and notes an exceptional risk-reward short setup.
At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M
Bruce C. Cozadd, a Board Member at Jazz Pharmaceuticals (NASDAQ: JAZZ), exercised stock options for 86,500 shares valued at $9,455,315, as disclosed in a recent SEC filing. The article also provides a company overview of Jazz Pharmaceuticals, focusing on its financial health, including revenue growth, gross margin, EPS, debt management, and various valuation ratios. It emphasizes the importance of insider transactions as part of a comprehensive investment analysis.
Zymeworks lifts 2026 revenue guidance by about $59 million after $250 million Ziihera milestone
Zymeworks has significantly increased its 2026 revenue guidance by about $59 million to $337-351 million, alongside raising its adjusted EBITDA guidance. This surge was primarily driven by a $250 million milestone payment from Jazz Pharmaceuticals following FDA approval for Ziihera's first-line HER2-positive GEA, which also turned the third quarter profitable with net income reaching $173.7 million. The updated guidance assumes antitrust clearance for the ZW209 deal with Roche.
Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook By Investing.com
Bernstein SocGen Group has reduced its price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) to $220 from $229, maintaining a Market Perform rating, due to expectations that Amgen’s Imdelltra will likely displace Jazz's Zepzelca in the small cell lung cancer market. Despite this, Jazz Pharmaceuticals reported record third-quarter revenue and its stock, currently trading above Bernstein's new target, appears undervalued according to InvestingPro analysis, with analysts revising earnings upwards.
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 7 November
This article announces a Form 144 filing for JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY, specifically for November 7. Form 144 is a notice of the intent to sell restricted stock. The article mentions JAZZ's stock performance, showing a 3.27% increase.
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 7 November
This article announces the filing of Form 144 for Jazz Pharmaceuticals Public Limited Company on November 7. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider transactions or sales by affiliates. The piece is brief and serves as an informational alert for investors following the company.
Form 4 Jazz Pharmaceuticals plc: Patricia Carr (SVP, Chief Accounting Officer) For: 4 November
This article reports on a Form 4 filing for Jazz Pharmaceuticals plc, indicating that Patricia Carr, the Senior Vice President and Chief Accounting Officer, had activity reported for November 4th. The filing is a standard regulatory disclosure related to changes in beneficial ownership of company securities by insiders.
Form 4 Jazz Pharmaceuticals plc: Patricia Carr (SVP, Chief Accounting Officer) For: 4 November
This article reports on a Form 4 filing for Jazz Pharmaceuticals plc, indicating that Patricia Carr, the SVP and Chief Accounting Officer, made a transaction on November 4th. Form 4 filings are legally required documents that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article also notes Jazz Pharmaceuticals plc's (JAZZ) stock performance, showing a 3.27% increase.
Form 4 Jazz Pharmaceuticals plc: Patricia Carr (SVP, Chief Accounting Officer) For: 4 November By Investing.com
This article reports on a Form 4 filing for Jazz Pharmaceuticals plc, indicating an insider transaction by Patricia Carr, the Senior Vice President and Chief Accounting Officer. The filing pertains to activity on November 4th. This news is specifically relevant to investors tracking insider trading within Jazz Pharmaceuticals.
Jazz Pharmaceuticals' Patricia Carr Executes 1,250 Stock Options and Sells Shares Above $231
Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals plc, executed 1,250 non-qualified stock options at $140.03 per share on November 4, 2026. On the same day, she sold 1,250 ordinary shares at $231.37 each and an additional 163 shares at $231.27. Following these transactions, Carr directly held 6,512 ordinary shares and retained 3,000 non-qualified stock options.
JAZZ Stock Earnings Review: Don’t Be Misled by Jazz Pharmaceuticals’ Apparent Wipe-Out
Jazz Pharmaceuticals (JAZZ) reported a record $1.24 billion in Q3 revenue, driven by strong sales in its sleep and oncology portfolios, leading to a raised full-year guidance for 2026. Despite a GAAP net loss of $483 million, largely due to a $754 million acquired in-process R&D charge from the Actio Biosciences acquisition, the underlying commercial business remains robust. The company's diversified portfolio and growth catalysts are seen as positive, though high debt and pipeline execution risks remain key considerations for investors.
Form 4 Jazz Pharmaceuticals plc: Bruce C. Cozadd (Director) For: 2 November
This article reports on a Form 4 filing by Jazz Pharmaceuticals plc, indicating director Bruce C. Cozadd's activity for November 2nd. The brief notice from Investing.com is part of their coverage of insider trading and company news.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its management will participate in three upcoming investor conferences in November and December 2026: the Jefferies London Global Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference, and Citi's 2026 Global Healthcare Conference. Audio webcasts of the fireside chats will be available on the company's investor relations website, with replays archived for 30 days.
Officer Renee D. Gala proposes selling 1,000 Jazz Pharmaceuticals (JAZZ) shares worth $225,370.
Renee D. Gala, an officer and director at Jazz Pharmaceuticals plc (JAZZ), has proposed selling 1,000 common shares valued at $225,370 on November 3, 2026. This notice, filed under Rule 144, specifies that the shares are restricted stock acquired on June 30, 2026. The filing also discloses two prior sales by Gala: 2,000 shares on October 6, 2026, for $472,800, and another 2,000 shares on September 8, 2026, for $486,060.
Jazz Pharmaceuticals (JAZZ) Sets Revenue Record As Pipeline News Reshapes The Story
Jazz Pharmaceuticals reported record quarterly revenue of US$1.24 billion and successfully launched Ziihera, a new cancer therapy, after FDA approval. The company also acquired Actio Biosciences, adding a rare epilepsy drug candidate to its pipeline. Despite a headline net loss of US$483.4 million, these strategic moves, along with a US$500 million buyback, aim to balance short-term earnings volatility with long-term cash flow and pipeline durability in oncology and neurology.
Jazz Pharmaceuticals to Join 3 Investor Conference Chats | JAZZ Stock News
Jazz Pharmaceuticals (JAZZ) announced its management will participate in fireside chats at three investor conferences in November and December 2026: the Jefferies London Global Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference, and Citi's 2026 Global Healthcare Conference. Audio webcasts of these chats will be available on the company's investor relations website, with replays archived for 30 days. The announcement includes specific dates and times for each conference.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its management will participate in three upcoming investor conferences: the Jefferies London Global Healthcare Conference on November 17, 2026, and the Piper Sandler 38th Annual Healthcare Conference and Citi's 2026 Global Healthcare Conference, both on December 2, 2026. Audio webcasts of these fireside chats will be available on the Investors section of the company's website, with replays archived for 30 days. The company, headquartered in Dublin, Ireland, focuses on developing life-changing medicines for patients with rare diseases.
Jazz Pharmaceuticals plc Raises 2026 Revenue Guidance After $1.2B Quarter
Jazz Pharmaceuticals reported record third-quarter revenue of $1.2 billion, a 10% increase year-over-year, leading to an increase in its full-year 2026 total revenue guidance. The company's net loss included a significant $754 million acquired IPR&D expense related to Actio. Additionally, Jazz Pharmaceuticals approved a new share buyback program up to $500 million and repurchased $225 million of ordinary shares in Q3, funded by cash from operations which totaled $1.3 billion for the nine months.
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Jazz Pharmaceuticals plc announced strong financial results for the third quarter of 2026, with total revenues reaching $1.2 billion, a 10% year-over-year increase. This performance led the company to raise its full-year 2026 total revenue guidance. Key highlights include the successful launch of Ziihera, continued growth of Xywav sales, and the acquisition of Actio Biosciences to expand its rare epilepsy portfolio.
Form 144 Jazz Pharmaceuticals Plc For: 3 November By Investing.com
This article from Investing.com announces the filing of Form 144 by Jazz Pharmaceuticals Plc for November 3, 2026. The content is brief, primarily serving as a notification of the filing, and includes market data for various indices, commodities, and stocks. The article does not provide details about the Form 144 filing itself.
Jazz Pharmaceuticals Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals reported record Q3 2026 revenues of $1.24 billion, a 10% year-over-year increase, driven by its oncology portfolio and the drug Xywav. The company raised its 2026 revenue guidance to $4.775-$4.85 billion, reflecting robust performance and strategic advancements like the successful launch of Zihera and the acquisition of Actio Biosciences to expand its rare epilepsy pipeline. Management expressed confidence in continued growth through strong product demand, new launches, pipeline expansion, and disciplined capital allocation.
Revenue hit $1.24B, but Jazz Pharmaceuticals (JAZZ) swung from profit to a Q3 loss.
Jazz Pharmaceuticals plc reported a net loss of $483.4 million in Q3 2026, a significant downturn from a net income of $251.4 million in the prior year, primarily due to $754.2 million in acquired in-process research and development expenses. Despite the loss, revenue increased to $1,243.0 million from $1,126.1 million in Q3 2025. The company also announced a new share repurchase program of up to $500.0 million and highlighted the acquisition of Actio for $820.0 million to strengthen its clinical pipeline.
Jazz Pharmaceuticals Q3 2026 Earnings: Revenue Rises 10% as Actio Charge Drives Loss
Jazz Pharmaceuticals reported a 10% increase in Q3 2026 revenue to $1.243 billion, driven by strong sales of Xywav and its oncology portfolio, leading to raised full-year guidance. However, a significant $754.2 million acquired in-process research and development charge from the Actio acquisition resulted in both GAAP and adjusted net losses for the quarter. Investors are advised to monitor pipeline execution, debt management, and the commercial sustainability of new product launches.
Jazz Pharmaceuticals And 2 Top Biotech Stocks To Watch
This article examines three biotech stocks – Jazz Pharmaceuticals, Arrowhead Pharmaceuticals, and Trulieve Cannabis – that are being closely watched by investors. It highlights how these companies, despite the high-risk nature of the biotech sector, offer strong financial positions and unique value propositions, from oncology and CNS therapies to RNAi-based medicines and medical cannabis products. The analysis delves into their current operations, future growth potential, and specific factors that could influence their long-term earnings and cash generation.
3 Healthcare Stocks To Own In October 2026
This article highlights three healthcare stocks – GeneDx Holdings (WGS), Axogen (AXGN), and Jazz Pharmaceuticals (JAZZ) – that offer compelling investment opportunities in October 2026. These companies represent leaders in genomic testing, peripheral nerve repair, and specialized pharmaceutical treatments, respectively, benefiting from advancements in AI and targeted medical technologies. The analysis delves into their current operations, financial positions, and potential future growth drivers, while also addressing inherent risks.
Jazz Pharmaceuticals plc (JAZZ) Interactive Stock Chart - Yahoo Finance
This page provides an interactive stock chart for Jazz Pharmaceuticals plc (JAZZ), along with its current stock price and recent market performance. It also lists upcoming corporate events, such as the Q3 2026 earnings call, and recent news articles related to the company and the biotech sector. The article includes a snapshot of Canadian market performance, showing key indices and commodities.
Jazz Pharmaceuticals (JAZZ) Following Fresh Ziihera Survival Data Looks Undervalued
Jazz Pharmaceuticals (JAZZ) is drawing attention after updated Phase 3 HERIZON GEA 01 data showed Ziihera-based regimens significantly cut mortality risk and achieved the longest reported median overall survival in its treatment setting. Despite a recent share price pullback, the company's long-term returns remain strong, and it currently screens as undervalued with an implied fair value of $294.27 against a last close of $206.78. The company's narrative is shifting towards an oncology-centric and cash-flow-durability story, with Ziihera as the main growth driver.
Jazz Pharmaceuticals (JAZZ) Following Fresh Ziihera Survival Data Looks Undervalued
Jazz Pharmaceuticals (JAZZ) appears undervalued after new Phase 3 HERIZON GEA 01 data showed its Ziihera-based regimens significantly reduced mortality risk and achieved the longest reported median overall survival in its treatment setting. Despite recent share price pullbacks, the stock has shown strong long-term gains, and analysts now view the company as 30% undervalued with a fair value of $294.27, driven by a shift to an oncology-centric and cash-flow-durable narrative, particularly focusing on Ziihera's growth potential.
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
Jazz Pharmaceuticals' financial performance is improving, largely driven by its expanding oncology business, which saw a nearly 32% year-over-year revenue increase in the second quarter. The company is actively diversifying its portfolio with promising new oncology drugs like Ziihera and Modeyso, reducing reliance on its established narcolepsy treatments. Despite competitive threats to its Xywav product, Jazz Pharmaceuticals appears to be an attractive investment for long-term holders due to its strong oncology pipeline and favorable valuation compared to the healthcare industry average.
JAZZ Q3'26 Earnings: revenue estimate is 1.21B USD
Jazz Pharmaceuticals plc (JAZZ) is scheduled to release its Q3'26 earnings on November 2nd, after market close, with an expected announcement at 4:00 PM ET. The company's revenue estimate for Q3'26 is $1.21 billion USD, and the anticipated EPS is $6.26 USD. This report provides a detailed breakdown of past revenue and EPS figures, alongside estimates and surprises.
Jazz Pharmaceuticals slips 3.9% as investors appear to reposition ahead of earnings
Jazz Pharmaceuticals (JAZZ) saw its stock price fall by 3.9% due to investor repositioning ahead of its Q3 2026 earnings report, a recent analyst price-target trim, and an October management-transition filing. Despite positive clinical data for Ziihera combinations, caution and profit-taking are occurring as the company prepares to release financial results on November 2, 2026. Insider trading shows 19 sales and no purchases in the last six months, further indicating a shift in sentiment.
Did Longer Survival Data Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?
Jazz Pharmaceuticals recently reported updated overall survival data from its Phase 3 HERIZON-GEA-01 trial, showing Ziihera-based regimens significantly extended median survival and reduced the risk of death for HER2+ gastroesophageal adenocarcinoma patients. This positive data reinforces Ziihera's recent FDA approvals and NCCN preferred status, strengthening its role as a key growth driver for Jazz Pharmaceuticals and potentially offsetting risks from legacy sleep products and high debt. The longer survival data is expected to boost physician confidence, support payer discussions, and influence investor perceptions of the company's oncology revenue potential.
What Jazz Pharmaceuticals Doubters Missed
Jazz Pharmaceuticals has seen a 23.6% return for investors this year, defying earlier doubts stemming from patent overhangs and reliance on older products. The company's recent FDA approval for Ziihera for HER2 positive gastroesophageal adenocarcinoma has bolstered the bullish case, suggesting new oncology and neuroscience products are successfully offsetting the erosion of oxybate revenue. While challenges like failed trials and acquisitions persist, the market now prices Jazz at US$214, with its fair value tied to successful execution in oncology and rare epilepsy pipelines.
New Survival Data in HER2-Positive Gastroesophageal Adenocarcinoma at ESMO 2026 - Jazz Pharmaceuticals
Jazz Pharmaceuticals announced via LinkedIn that it will be presenting new Phase 3 data, including 3-year survival follow-up results, for its treatment in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) at ESMO 2026. These findings underscore the company's progress in GEA and its dedication to providing effective treatment options for cancer patients and their families.
Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced updated three-year overall survival data for Ziihera (zanidatamab-hrii) in HER2-positive advanced gastroesophageal adenocarcinoma (GEA) from the Phase 3 HERIZON-GEA-01 trial. Patients receiving Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 27.0 months, significantly improving upon trastuzumab plus chemotherapy. The FDA had previously approved two Ziihera-containing regimens for first-line HER2+ GEA in August 2026.
Jazz drug shows survival benefit in stomach cancer trial
Jazz Pharmaceuticals announced updated results from a Phase 3 trial showing its drug Ziihera, when combined with chemotherapy, significantly extended overall survival in patients with HER2-positive gastroesophageal adenocarcinoma. The combination of Ziihera, tislelizumab, and chemotherapy reduced the risk of death by 35% compared to trastuzumab plus chemotherapy, with a median overall survival of 27.0 months. The FDA had previously approved two Ziihera-containing regimens for this condition on August 25, 2026.
Jazz Pharmaceuticals plc Estimates – NASDAQ:JAZZ
This article provides access to financial actuals and analyst estimates for Jazz Pharmaceuticals plc (NASDAQ: JAZZ) through TradingView. Users can explore reported financial data and compare it with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also visualizes trends over time, offering both annual and quarterly perspectives.
Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Jazz Pharmaceuticals plc (JAZZ), including updates on its stock performance and various related news items from different financial sources. It covers topics like upcoming financial results, discussions around medical cannabis investments, and analyst concerns regarding healthcare stocks. The article also includes a performance overview comparing JAZZ's returns against the S&P 500 benchmark.
Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ)
This article provides a detailed stock quote and performance overview for Jazz Pharmaceuticals plc (JAZZ), including its current price, trading volume, and 52-week range. It also features a collection of recent news headlines and research articles related to the company, covering topics like financial performance, analyst ratings, and product developments. The information is presented with a focus on investment data and market trends.
Jazz Pharmaceuticals stock trades at EUR 185.18 ahead of November 2 results
Jazz Pharmaceuticals stock is trading at EUR 185.18 as the company prepares to release its third-quarter results on November 2, 2026, after the U.S. market close. The company reported second-quarter revenue of USD 1.21 billion, a 15.5 percent increase year-over-year, but adjusted earnings per share missed consensus estimates. Investors are now focused on the upcoming report to see if revenue growth continues and earnings recover, especially following the recent withdrawal of Zepzelca's second-line indication.
Jazz Pharmaceuticals stock trades at EUR 185.18 ahead of November 2 results
Jazz Pharmaceuticals (JAZZ) stock is trading at EUR 185.18 ahead of its Q3 2026 results release on November 2, 2026. The company reported Q2 revenue of USD 1.21 billion, up 15.5%, but adjusted EPS missed estimates. Investors will be watching the upcoming report to see if revenue growth continues and earnings recover, especially following the recent withdrawal of Zepzelca's second-line indication.
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals (JAZZ) announced it will release its third quarter financial results for 2026 on Monday, November 2, 2026, after the close of the U.S. markets. The company will also host a live conference call and webcast on the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results and provide a business update. A replay of the webcast will be available for approximately one week.
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it will release its 2026 third-quarter financial results on Monday, November 2, 2026, after the U.S. financial markets close. The company will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update. Interested parties can register in advance via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it will report its 2026 third-quarter financial results on Monday, November 2, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update. Interested parties can register for the call via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc (JAZZ) Stock forecasts
Argus has lowered its target price for Jazz Pharmaceuticals (JAZZ) to $244.00 as of September 30, 2026. The biopharmaceutical firm, domiciled in Ireland, specializes in treatments for sleeping disorders and oncology. The current price for JAZZ is $210.23.